---
title: "Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Efficacy and safety"
description: "Formulary evidence on Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Efficacy and safety. 1 evidence topic quoted from 5 sources."
canonical: "https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/executive-summary/efficacy-and-safety"
published: "2026-11-15T22:20:57-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Efficacy and safety

<a id="heading-1.1.2"></a>

## 1.1.2 Claseprubart Efficacy and Safety

<a id="topic-1.1.2-1"></a>

### Summary

No randomized efficacy results for claseprubart in CIDP have been reported. CAPTIVATE is a phase 3 trial with an open-label Part A, in which participants receive claseprubart 300 mg subcutaneously every 2 weeks after an intravenous loading dose, followed by a randomized, placebo-controlled withdrawal Part B with time to relapse on the adjusted INCAT score as the primary endpoint. In the interim responder analysis of Part A, 30 of the first 40 participants (75%) were confirmed responders, defined as a decrease of at least 1 point in the adjusted INCAT score, against a target response rate of 50% or greater. Of the 10 non-responders, 5 had stable CIDP and 5 had a relapse. In confirmed responders, the mean (SD) change from Part A baseline was –1.6 (0.89) on INCAT, 15.9 (12.78) in grip strength, 5.1 (3.93) on the MRC-SS, and 8.9 (12.08) on I-RODS.

In the same interim analysis set (N=40), 24 participants (60%) had an adverse event and 1 (3%) had a serious adverse event, a grade 3 ureterolithiasis assessed as not treatment-related. No treatment-related infections, serious infections, or adverse events leading to discontinuation were reported. In the phase 1 study in healthy volunteers, no serious adverse events were reported, five participants had mild or moderate treatment-related adverse events, and two participants in the 50 mg/kg intravenous cohort became antinuclear antibody positive at Day 57 without evidence of SLE.

These results are from an interim analysis of the open-label Part A; the company describes the summaries as preliminary and states that the study remains ongoing and the data are not final. Top-line results from all participants completing Part A are expected by the end of 2027 and from Part B by the end of 2028.

Source: [Allen et al. (2026d)](https://investor.dianthustx.com/static-files/61f3f3f9-f022-43e3-86d2-8534e2df4ac9); [Allen et al. (2026e)](https://investor.dianthustx.com/static-files/961065e9-6810-4689-9656-4d0db7372ec3); [Dianthus Therapeutics Form 10-Q (2026c)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000040/dnth-20260930.htm); [Dianthus Therapeutics presentation (2024a)](https://www.sec.gov/Archives/edgar/data/1690585/000095017024002707/dnth-ex99_1.htm); [ClinicalTrials.gov NCT06858579](https://clinicaltrials.gov/study/NCT06858579)

## Related pages
- [Claseprubart (DNTH103): Chronic inflammatory demyelinating polyneuropathy](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Terms and abbreviations](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/terms-and-abbreviations.md)
- [Claseprubart (DNTH103): Chronic inflammatory demyelinating polyneuropathy](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/executive-summary) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/executive-summary.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Product information and disease description](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/product-information-and-disease-description.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Clinical evidence](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/clinical-evidence.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Economic information and modeling report](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/economics) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/economics.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: References](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/references) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/references.md)
